Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Cincinnati, Ohio

This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10564
Shown on this page
12
Current sort
Recently updated
Location scope
Cincinnati, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Cincinnati, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 1057–1068 of 10,564 matching trials in Cincinnati, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Suspended Not applicable Interventional

Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

NCT07449325
View directory record Official record
Conditions
Angina Pectoris, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Vascular Diseases, Microvascular Angina
Interventions
A-FLUX Reducer System
Device
Lead sponsor
VahatiCor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 3 Interventional Results available

A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

NCT05156047
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Open-label Pitolisant, Double-blind Placebo, Double-blind Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
58
States / cities
Peoria, Arizona • Scottsdale, Arizona • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Recruiting Phase 3 Interventional

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
66
States / cities
Daphne, Alabama • Springdale, Arkansas • Duarte, California + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

NCT04421248
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Combined
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Donald Gilbert, MD, MS, FAAN, FAAP
Other
Eligibility
8 Years to 12 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 4 Interventional

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

NCT04891640
View directory record Official record
Conditions
Juvenile Spondyloarthritis
Interventions
Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Phase 3 Interventional Results available

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408
View directory record Official record
Conditions
Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
Relacorilant 150 mg, Nab-paclitaxel 80 mg/m^2, Nab-paclitaxel 100 mg/m^2
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Completed No phase listed Observational

Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients

NCT00308802
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney transplantation
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Terminated Phase 3 Interventional Results available

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

NCT05605093
View directory record Official record
Conditions
COVID-19
Interventions
Shionogi Protease Inhibitor (S-217622), placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
103
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

NCT01511562
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cytarabine, etoposide, thiotepa, stem cell transplant, G-CSF
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
126
States / cities
Anchorage, Alaska • Burbank, California • La Jolla, California + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Active, not recruiting Not applicable Interventional

SELUTION 4 De Novo Small Vessel IDE Trial

NCT05946629
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
65
States / cities
Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Recruiting Not applicable Interventional

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

NCT05172960
View directory record Official record
Conditions
Aortic Stenosis, Severe
Interventions
SAPIEN X4 THV, SAPIEN X4S
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
58
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 1:55 PM EST
Recruiting Not applicable Interventional

A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer

NCT07223463
View directory record Official record
Conditions
Cancer, Medication Adherence
Interventions
Tailored Program, Feedback Program (Uniform Standard of Care)
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 24 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Kansas City, Kansas • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 15, 2026, 1:55 PM EST